/ /

Laird Harrison
Anti-VEGF patients feel anxiety and depression
Patients receiving anti-vascular endothelial growth factor (VEGF) injections for neovascular (wet) age-related macular degeneration (AMD) often feel anxiety and depression about the treatment, researchers say.
Promising advances in uveal melanoma treatment
Promising advances in uveal melanoma treatment
Immunotherapy and other investigational treatments appear to be promising for uveal melanoma, according to Carol Shields, MD. “There have been interesting new avenues for therapy,” said Dr. Shields, co-director, Ocular Oncology Service, Wills Eye Hospital, Philadelphia.
UK opticians call for mediation service
The UK Federation of (Ophthalmic and Dispensing) Opticians (FODO) is calling for a mediation service to handle disputes over refractive surgery.
Gene therapy trial launched for X-linked retinitis pigmentosa
Researchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP).
Patients’ health jeopardized by failed ophthalmology follow-up
Failure to follow-up after ophthalmology appointments can damage patients’ health, a new study suggests. “In our view, national consideration should be given to create targets for reporting how well providers are managing follow-up patients,” reported A Davis and colleagues in the journal Eye.
Aldehyde dehydrogenase implicated in mucous membrane pemphigoid
Preliminary studies suggest disulfiram could aid in the treatment of mucous membrane pemphigoid (MMP). Used topically, the drug may inhibit aldehyde deydrogenase (ALDH), which plays a key role in fibrosis, wrote JK Dart, UCL Institute of Ophthalmology, London.
Evidence weak for blue light-filtering IOLs
Only weak evidence supports the use of IOLs that filter visible blue light, researchers say. “On the basis of currently available evidence, one cannot advocate for the use of blue-light-filtering IOLs over UV-only filtering IOLs,” wroite X. Li, Waterford Institute of Technology, Waterford, Ireland, and colleagues.
Lifitegrast data support dry eye efficacy over placebo drops
Lifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Haze after PRK, LASIK tied to faulty epithelial regrowth
Haze after PRK, LASIK tied to faulty epithelial regrowth
Poor regeneration of the epithelial basement accounts for most 'late haze' associated with PRK, LASIK, infections, or corneal transplants. Proper excimer laser maintenance may reduce irregularities.